Our collaborative group leverages recent advances in stable isotope tracer based NMR and mass spectrometry-driven untargeted metabolomics technologies to reveal the metabolic origins of disease and targets for therapy. Complex in vivo phenotyping methodologies are strategically aligned with these sophisticated chemical profiling platforms to generate high resolution phenotypic pictures. In addition to our mouse studies, we perform studies in humans to learn how alterations of ketone metabolism and related pathways may serve as diagnostic biomarkers and therapeutic targets for obesity, diabetes, NAFLD/NASH, heart failure/CHF, and metabolic maladaptations that can occur in any disease state.